Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 52, Issue 1

Issues

Total plasma Nε-(carboxymethyl)lysine and sRAGE levels are inversely associated with a number of metabolic syndrome risk factors in non-diabetic young-to-middle-aged medication-free subjects

Katarína Šebeková
  • Corresponding author
  • Medical Faculty, Institute of Molecular BioMedicine, Comenius University, Sasinkova 4, 811 08 Bratislava, Slovakia
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Zora Krivošíková
  • Medical Faculty, Department of Clinical and Experimental Pharmacotherapy, Slovak Medical University, Bratislava, Slovakia
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Martin Gajdoš
  • Medical Faculty, Department of Clinical and Experimental Pharmacotherapy, Slovak Medical University, Bratislava, Slovakia
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2013-03-18 | DOI: https://doi.org/10.1515/cclm-2012-0879

Abstract

Background: Interaction of advanced glycation end products (AGEs) with their specific cell-surface receptor for AGEs (RAGE) induces production of reactive oxygen species, pro-diabetic, pro-inflammatory, and pro-atherogenic responses. The metabolic syndrome (Metsy) imposes a high risk of development of cardiovascular disease and unequivocally predisposes the non-diabetics to type 2 diabetes mellitus. The aim of the study was to investigate the association between circulating soluble RAGE (sRAGE), Nε-(carboxymethyl)lysine (CML) or AGE-associated fluorescence of plasma (AGE-Fl) with the number of manifested Metsy risk factors in young-to-middle-aged medication-free non-diabetic subjects.

Methods: Metsy was classified according to NCEP/ATP III criteria; plasma sRAGE and total CML were determined by ELISA methods and AGE-Fl fluorimetrically.

Results: From among 437 participants aged 33±11 years, 58% were females. In total 174 subjects were Metsy risk factors-free, 142 presented one, 59 presented two risk factors, and 62 suffered from Metsy. Plasma sRAGE and CML/albumin levels decreased with increasing number of Metsy risk factors (p<0.01, both), while AGE-Fl/albumin levels remained similar. Multivariate analysis selected waist circumference as a main determinant of plasma sRAGE as well as CML/albumin levels.

Conclusions: In young-to-middle-aged non-diabetic medication-free subjects plasma total CML/albumin and sRAGE levels decrease prior to the manifestation of Metsy. With regards to RAGE-mediated CML trapping into adipose tissue inducing dysregulation of pro-inflammatory cytokines, adipokines, and the development of obesity-related insulin resistance, and the potential involvement of sRAGE in feedback regulation of the toxic effects of AGE/RAGE-mediated signaling, this early decline might be of clinical impact in development of type 2 diabetes and its complications.

This article offers supplementary material which is provided at the end of the article.

Keywords: central obesity; healthy subjects; metabolic syndrome; Nε-(carboxymethyl)lysine (CML); sRAGE

References

  • 1.

    Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997;51:1170–81.PubMedCrossrefGoogle Scholar

  • 2.

    Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 2005;83:876–86.PubMedCrossrefGoogle Scholar

  • 3.

    Nakamura K, Yamagishi SI, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc Res 2008;76: 52–6.Google Scholar

  • 4.

    Goh SY, Cooper ME. The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008;93:1143–52.PubMedCrossrefGoogle Scholar

  • 5.

    Yamagishi S, Maeda S, Matsui T, Ueda S, Fukami K, Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim Biophys Acta 2012;1820:663–71.Web of ScienceGoogle Scholar

  • 6.

    Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112: 3066–72.Google Scholar

  • 7.

    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome – An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–52.PubMedCrossrefGoogle Scholar

  • 8.

    Sjogren P, Basta G, de Caterina R, Rosell M, Basu S, Silveira A, et al. Markers of endothelial activity are related to components of the metabolic syndrome, but not to circulating concentrations of the advanced glycation end-product N epsilon-carboxymethyl-lysine in healthy Swedish men. Atherosclerosis 2007;195:E168–75.Web of ScienceGoogle Scholar

  • 9.

    Tahara N, Yamagishi S, Matsui T, Takeuchi M, Nitta Y, Kodama N, et al. serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc Ther 2012;30:42–8.CrossrefWeb of SciencePubMedGoogle Scholar

  • 10.

    Semba RD, Arab L, Sun K, Nicklett EJ, Ferrucci L. Fat mass is inversely associated with serum carboxymethyl-lysine, an advanced glycation end product, in adults. J Nutr 2011;141:1726–30.Google Scholar

  • 11.

    Tan KC, Shiu SW, Wong Y, Tam X. Serum advanced glycation end products (AGEs) are associated with insulin resistance. Diabetes Metab Res Rev 2011;27:488–92.PubMedCrossrefGoogle Scholar

  • 12.

    Klenovicsova K, Krivosikova Z, Gajdos M, Sebekova K. Association of sVAP-1, sRAGE, and CML with lactation-induced insulin sensitivity in young non-diabetic healthy women. Clin Chim Acta 2011;412:1842–7.Web of ScienceGoogle Scholar

  • 13.

    Sebekova K, Somoza V, Jarcuskova M, Heidland A, Podracka L. Plasma advanced glycation end products are decreased in obese children compared with lean controls. Int J Pediatr Obes 2009;4:112–8.Web of ScienceCrossrefPubMedGoogle Scholar

  • 14.

    McNulty M, Mahmud A, Feely J. Advanced glycation end-products and arterial stiffness in hypertension. Am J Hypertens 2007;20:242–7.Web of ScienceCrossrefPubMedGoogle Scholar

  • 15.

    Tam XH, Shiu SW, Leng L, Bucala R, Betteridge DJ, Tan KC. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. Clin Sci (Lond) 2011;120:81–9.Web of ScienceGoogle Scholar

  • 16.

    Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006;91:4628–34.CrossrefGoogle Scholar

  • 17.

    Devangelio E, Santilli F, Formoso G, Ferroni P, Bucciarelli L, Michetti N, et al. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 2007;43:511–8.Web of ScienceGoogle Scholar

  • 18.

    Yan XX, Lu L, Peng WH, Wang LJ, Zhang Q, Zhang RY, et al. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 2009;205:544–8.Google Scholar

  • 19.

    Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006;49:2756–62.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 20.

    Grossin N, Wautier MP, Meas T, Guillausseau PJ, Massin P, Wautier JL. Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes Metab 2008;34:392–5.CrossrefPubMedGoogle Scholar

  • 21.

    Geroldi D, Falcone C, Emanuele E, D’Angelo A, Calcagnino M, Buzzi MP, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005;23:1725–9.PubMedCrossrefGoogle Scholar

  • 22.

    Derosa G, D’Angelo A, Mugellini A, Pesce RM, Fogari E, Maffioli P. Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study. Curr Med Res Opin 2012;28:1435–45.Web of ScienceGoogle Scholar

  • 23.

    Kim OY, Jo SH, Jang Y, Chae JS, Kim JY, Hyun YJ, et al. G allele at RAGE SNP82 is associated with proinflammatory markers in obese subjects. Nutr Res 2009;29:106–13.Web of ScienceGoogle Scholar

  • 24.

    Norata GD, Garlaschelli K, Grigore L, Tibolla G, Raselli S, Redaelli L, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr Metab Cardiovasc Dis 2009;19:129–34.Web of SciencePubMedCrossrefGoogle Scholar

  • 25.

    de Giorgis T, D’Adamo E, Giannini C, Chiavaroli V, Scarinci A, Verrotti A, et al. Could receptors for advanced glycation end products be considered cardiovascular risk markers in obese children? Antioxid Redox Signal 2012;17:187–91.Web of ScienceGoogle Scholar

  • 26.

    Falcone C, Emanuele E, D’Angelo A, Buzzi MP, Belvito C, Cuccia M, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005;25:1032–7.CrossrefPubMedGoogle Scholar

  • 27.

    Koyama H, Yamamoto H, Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med 2007;13:625–35.PubMedGoogle Scholar

  • 28.

    McNair ED, Wells CR, Qureshi M, Basran R, Pearce C, Orvold J, et al. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention. Clin Cardiol 2010;33:678–85.CrossrefPubMedGoogle Scholar

  • 29.

    National kidney foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1–266.Google Scholar

  • 30.

    Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402–10.PubMedCrossrefGoogle Scholar

  • 31.

    Munch G, Keis R, Wessels A, Riederer P, Bahner U, Heidland A, et al. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 1997;35:669–77.PubMedGoogle Scholar

  • 32.

    Basta G, Leonardis D, Mallamaci F, Cutrupi S, Pizzini P, Gaetano L, et al. Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int 2010;77: 225–31.Web of ScienceCrossrefPubMedGoogle Scholar

  • 33.

    Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004;63:582–92.CrossrefGoogle Scholar

  • 34.

    Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, N-(epsilon)(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996;271:9982–6.Google Scholar

  • 35.

    Schillaci G, Pirro M. C-reactive protein in hypertension: clinical significance and predictive value. Nutr Metab Cardiovasc Dis 2006;16:500–8.PubMedCrossrefGoogle Scholar

  • 36.

    van der Velde M, Bello AK, Brantsma AH, El Nahas M, Bakker SJ, de Jong PE, et al. Do albuminuria and hs-CRP add to the International Diabetes Federation definition of the metabolic syndrome in predicting outcome? Nephrol Dial Transplant 2012;27:2275–83.Web of ScienceGoogle Scholar

  • 37.

    Semba RD, Beck J, Sun K, Egan JM, Carlson OD, Varadhan R, et al. Relationship of a dominant advanced glycation end product, serum carboxymethyl-lysine, and abnormal glucose metabolism in adults: the Baltimore longitudinal study of aging. J Nutr Health Aging 2010;14:507–13.CrossrefPubMedGoogle Scholar

  • 38.

    Gaens KH, Niessen PM, van Greevenbroek MM, van der Kallen CH, Niessen HW, Rensen SR, et al. Nε-Carboxymethyllysine–RAGE axis: a novel link between obesity, inflammation and insulin resistance. 11th Maillard Reaction Symposium, Nancy, France. 2012:200–1.Google Scholar

  • 39.

    Miller AA, De Silva TM, Jackman KA, Sobey CG. Effect of gender and sex hormones on vascular oxidative stress. Clin Exp Pharmacol Physiol 2007;34:1037–43.CrossrefWeb of ScienceGoogle Scholar

  • 40.

    Ide T, Tsutsui H, Ohashi N, Hayashidani S, Suematsu N, Tsuchihashi M, et al. Greater oxidative stress in healthy young men compared with premenopausal women. Arterioscler Thromb Vasc Biol 2002;22:438–42.CrossrefPubMedGoogle Scholar

  • 41.

    Somoza V, Wenzel E, Weiss C, Clawin-Radecker I, Grubel N, Erbersdobler HF. Dose-dependent utilisation of casein-linked lysinoalanine, N(epsilon)-fructoselysine and N(epsilon)-carboxymethyllysine in rats. Mol Nutr Food Res 2006;50:833–41.PubMedCrossrefGoogle Scholar

  • 42.

    Delgado-Andrade C, Tessier FJ, Niquet-Leridon C, Seiquer I, Navarro MP. Study of the urinary and faecal excretion of N (epsilon)-carboxymethyllysine in young human volunteers. Amino Acids 2012;43:595–602.CrossrefWeb of ScienceGoogle Scholar

  • 43.

    McNair ED, Wells CR, Qureshi AM, Basran R, Pearce C, Orvold J, et al. Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products. Mol Cell Biochem 2010;341:135–8.Web of ScienceGoogle Scholar

  • 44.

    Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005;25: 2587–93.PubMedCrossrefGoogle Scholar

  • 45.

    Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003;370:1097–109.Google Scholar

  • 46.

    Yamagishi S, Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K, et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006;55:1227–31.CrossrefPubMedGoogle Scholar

  • 47.

    Galichet A, Weibel M, Heimann CW. Calcium-regulated intramembrane proteolysis of the RAGE receptor. Biochem Biophys Res Commun 2008;370:1–5.Web of ScienceGoogle Scholar

  • 48.

    Zhang L, Bukulin M, Kojro E, Roth A, Metz VV, Fahrenholz F, et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 2008;283:35507–16.Web of ScienceGoogle Scholar

  • 49.

    Gopal P, Rutten EP, Dentener MA, Wouters EF, Reynaert NL. Decreased plasma sRAGE levels in COPD: influence of oxygen therapy. Eur J Clin Invest 2012;42:807–14.PubMedCrossrefGoogle Scholar

  • 50.

    Mokan M, Galajda P, Pridavkova D, Tomaskova V, Sutarik L, Krucinska L, et al. Prevalence of diabetes mellitus and metabolic syndrome in Slovakia. Diabetes Res Clin Pract 2008;81:238–42.CrossrefPubMedGoogle Scholar

About the article

Corresponding author: Assoc. Prof. Katarína Šebeková, MD, DSc, Medical Faculty, Institute of Molecular BioMedicine, Comenius University, Sasinkova 4, 811 08 Bratislava, Slovakia, Phone: +421 2 59357429, Fax: +421 2 59357631, E-mail:


Received: 2012-12-14

Accepted: 2013-02-04

Published Online: 2013-03-18

Published in Print: 2014-01-01


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 52, Issue 1, Pages 139–149, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2012-0879.

Export Citation

©2014 by Walter de Gruyter Berlin Boston.Get Permission

Supplementary Article Materials

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Kenny Mendoza-Herrera, Celia Aradillas-García, Miguel Mejía-Diaz, Jorge Alegría-Torres, Ma. Garay-Sevilla, and Claudia Luevano-Contreras
Medicines, 2018, Volume 5, Number 4, Page 128
[2]
Katarína Šebeková and Katarína Brouder Šebeková
Experimental Gerontology, 2018
[3]
Ma. Eugenia Garay-Sevilla, Sofía Torres-Graciano, Ma. Etzabel Villegas-Rodríguez, Antonio E. Rivera-Cisneros, Katarzyna Wrobel, and Jaime Uribarri
Acta Paediatrica, 2018
[4]
Vendula Bartakova, Radana Kollarova, Katarina Kuricova, Katarina Sebekova, Jana Belobradkova, and Katerina Kankova
Biomedical Papers, 2016, Volume 160, Number 1, Page 70
[6]
Barbora de Courten, Maximilian PJ de Courten, Georgia Soldatos, Sonia L Dougherty, Nora Straznicky, Markus Schlaich, Karly C Sourris, Vibhasha Chand, Jean LJM Scheijen, Bronwyn A Kingwell, Mark E Cooper, Casper G Schalkwijk, Karen Z Walker, and Josephine M Forbes
The American Journal of Clinical Nutrition, 2016, Volume 103, Number 6, Page 1426
[7]
Susana A. Palma-Duran, Meropi D. Kontogianni, Antonis Vlassopoulos, Shudong Zhao, Aikaterini Margariti, Michael Georgoulis, George Papatheodoridis, and Emilie Combet
Metabolism, 2018
[8]
Claire K. Inman, Abdullah Al Junaibi, Hyunwook Koh, Abdishakur Abdulle, Raghib Ali, Abdullah Al Naeemi, Eiman Al Zaabi, Naima Oumeziane, Marina Al Bastaki, Mohammed Al Houqani, Fatma Al Maskari, Ayesha Al Dhaheri, Syed M. Shah, Laila Abdel Wareth, Wael Al Mahmeed, Habiba Alsafar, Fatme Al Anouti, Ayesha Al Hosani, Muna Haji, Divya Galani, Matthew J. O'Connor, Jiyoung Ahn, Tomas Kirchhoff, Scott Sherman, Richard B. Hayes, Huilin Li, Ravichandran Ramasamy, and Ann Marie Schmidt
Journal of Clinical & Translational Endocrinology, 2017
[9]
Magdalena Pertynska-Marczewska and Zaher Merhi
Reproductive Sciences, 2015, Volume 22, Number 7, Page 774
[12]
Chih-Tsueng He, Chien-Hsing Lee, Chang-Hsun Hsieh, Fone-Ching Hsiao, Philip Kuo, Nain-Feng Chu, and Yi-Jen Hung
International Journal of Endocrinology, 2014, Volume 2014, Page 1
[13]
K. Simon Klenovics, R. Kollárová, J. Hodosy, P. Celec, and K. Šebeková
Diabetic Medicine, 2014, Volume 31, Number 5, Page 581
[14]
F. Santilli, N. Vazzana, P. Iodice, S. Lattanzio, R. Liani, R. G. Bellomo, G. Lessiani, F. Perego, R. Saggini, and G. Davì
Thrombosis and Haemostasis, 2013, Volume 110, Number 6, Page 1232

Comments (0)

Please log in or register to comment.
Log in